Study record
Urolithin A and age-related immune decline (2025)
Human RCT — biomarker endpoint
○ Evidence tier 4 — Human RCT — biomarker endpoint
Record verify: primary source pending
| Design | Randomized, placebo-controlled trial (biomarker) |
| DOI | 10.1038/s43587-025-00996-x |
| Citation status | doi verified via Crossref 2026-07-12 (Nature Aging 2025;5:2309-2322, 'Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial'). PMID + NCT: needs_primary_fulltext. |
Five-qualifier claim
| Species / population | Older adults with age-related immune decline (randomized, placebo-controlled trial). |
| Exposure, route, schedule | Oral urolithin A for several months. |
| Comparator / duration | Placebo-controlled, randomized. |
| Endpoint / numeric result | Reported improvements in immune-cell/mitochondrial biomarkers associated with aging immune function. |
| What it did NOT establish | Immune-biomarker endpoints — not a functional disability, disease-outcome, or lifespan endpoint, and not a healthy-aging-longevity result. |
Interventions
Primary reference
https://doi.org/10.1038/s43587-025-00996-x
Exact identifier confirmed against the primary record via Crossref/ClinicalTrials.gov where stated in the citation status; anything marked needs_primary_fulltext is not yet confirmed.